This core will provide support for the breeding and tracking of all of the special mutant(knockout) or transgenic mice needed to conduct the experiments proposed in projects 1-3. Our premise is that, to ensure most efficient use of mice in the 3 projects (and to ensure that the interacting projects use mice which have an identical history of breeding and care), mouse care and breeding is best performed by a single facility, which will maintain colonies of each strain and coordinate their use. By providing the mice from a core within the Asthma center, each of the scientific projects requiring mice can concentrate on achieving their basic scientific goals. The Core will be located in The Simon C. Fireman Research Center Animal Facility. This facility, which is located on the floor below that of Drs. Kinet and GalIi, is fully accredited by AAAAAC and the USDA and is staffed by qualified animal care personnel and a licensed veterinarian. In addition to directing the breeding of each colony and tracking mouse genotypes where appropriate, Core personnel will be responsible for carrying out certain pre-experimental treatment protocols. Once breeding is underway at full scale, core personnel will also be responsible for coordinating the use of mice and distributing mice of appropriate age and genotype to the various participating investigators. Furthermore, the personnel will be responsible for keeping appropriate records on the breeding, health, and genotypes of all mice and making sure that these records are available to all investigators. In this way, mice of the appropriate genotype and age, and of uniformly high quality, will be available to all investigators.

Project Start
2000-09-01
Project End
2001-08-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
4
Fiscal Year
2000
Total Cost
$191,152
Indirect Cost
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02215
Wang, Hai-Bin; Ghiran, Ionita; Matthaei, Klaus et al. (2007) Airway eosinophils: allergic inflammation recruited professional antigen-presenting cells. J Immunol 179:7585-92
Gotlib, Jason; Berube, Caroline; Growney, Joseph D et al. (2005) Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 106:2865-70
Maurer, Marcus; Galli, Stephen J (2004) Lack of significant skin inflammation during elimination by apoptosis of large numbers of mouse cutaneous mast cells after cessation of treatment with stem cell factor. Lab Invest 84:1593-602
Tedla, Nicodemus; Bandeira-Melo, Christianne; Tassinari, Paolo et al. (2003) Activation of human eosinophils through leukocyte immunoglobulin-like receptor 7. Proc Natl Acad Sci U S A 100:1174-9
Bandeira-Melo, Christianne; Woods, Lesley J; Phoofolo, Mojabeng et al. (2002) Intracrine cysteinyl leukotriene receptor-mediated signaling of eosinophil vesicular transport-mediated interleukin-4 secretion. J Exp Med 196:841-50
Sayama, Koichi; Diehn, Maximilian; Matsuda, Kentaro et al. (2002) Transcriptional response of human mast cells stimulated via the Fc(epsilon)RI and identification of mast cells as a source of IL-11. BMC Immunol 3:5
Bandeira-Melo, Christianne; Hall, John C; Penrose, John F et al. (2002) Cysteinyl leukotrienes induce IL-4 release from cord blood-derived human eosinophils. J Allergy Clin Immunol 109:975-9
Asai, K; Kitaura, J; Kawakami, Y et al. (2001) Regulation of mast cell survival by IgE. Immunity 14:791-800
Bandeira-Melo, C; Sugiyama, K; Woods, L J et al. (2001) Cutting edge: eotaxin elicits rapid vesicular transport-mediated release of preformed IL-4 from human eosinophils. J Immunol 166:4813-7
Bandeira-Melo, C; Phoofolo, M; Weller, P F (2001) Extranuclear lipid bodies, elicited by CCR3-mediated signaling pathways, are the sites of chemokine-enhanced leukotriene C4 production in eosinophils and basophils. J Biol Chem 276:22779-87

Showing the most recent 10 out of 17 publications